How to Get Evenity (Romosozumab) in District of Columbia

Romosozumab-aqqg, sold under the brand name Evenity, is a monoclonal antibody administered as a monthly injection over 12 months that works by blocking sclerostin. The FDA has approved romosozumab for postmenopausal women with osteoporosis who face a substantial fracture risk. This article explains the process for DC residents seeking romosozumab, including which providers may prescribe it, prior authorization procedures, and the scope of what DC pharmacies can dispense. The cost details, insurance plan requirements, and appeal deadlines provided here change frequently and should be verified directly with your insurer or the DC Medicaid program when you are ready to start romosozumab therapy, rather than relied upon as current information.

The rate-limiting step for most DC patients is not finding a prescriber. It is clearing insurer prior authorization with complete lab and DXA documentation. Romosozumab is FDA-approved with a boxed warning for cardiovascular risk (myocardial infarction, stroke, cardiovascular death), and it is contraindicated in patients with an MI or stroke within the preceding year, per the FDA prescribing information. DC has full-practice-authority nurse practitioners, telehealth parity requirements, and Medicaid coverage with prior authorization, all of which make access logistically easier here than in many states, but none of that shortens the insurer review step.

Who is a candidate for Evenity in DC

Evenity is approved for postmenopausal women with osteoporosis who are at high risk for fracture: a prior osteoporotic fracture, multiple clinical risk factors, or failure of or intolerance to another osteoporosis therapy. Clinicians generally reserve it for patients who meet "very high fracture risk" criteria described in professional guidelines, such as a recent vertebral fracture, a T-score at or below -3.0, or a high FRAX-estimated probability. Confirm current guideline thresholds with your prescriber; guideline documents are periodically updated and this page does not reproduce a specific citation for them because the source citation could not be verified.

Patients with a myocardial infarction or stroke in the past 12 months are excluded under the FDA label's boxed warning. Uncorrected hypocalcemia is also a contraindication.

In the pivotal ARCH trial, romosozumab reduced new vertebral fractures compared with alendronate over 24 months, but the trial also recorded a numerically higher rate of adjudicated cardiovascular events in the romosozumab arm. The exact percentages commonly cited for this trial vary by source and should be checked against the primary published trial report or a current systematic review before being used in patient counseling; they are not reproduced here as precise figures because the underlying citation could not be confirmed.

Who can prescribe it in DC

MDs and DOs can prescribe Evenity independently. DC is a full-practice-authority state for nurse practitioners, meaning an NP can evaluate, diagnose, and prescribe without physician supervision, though the specific statutory citation should be verified with DC's Board of Medicine rather than assumed from this page. Physician assistants can prescribe under a collaborative agreement with a supervising physician.

In practice, endocrinologists and rheumatologists write most romosozumab prescriptions in DC, and primary care physicians experienced in osteoporosis management sometimes do as well. Academic medical center bone health clinics (for example, those affiliated with Georgetown, GW, and MedStar) have experience with the prior authorization paperwork this drug requires. The prescriber is rarely the bottleneck; insurer review usually is.

Telehealth: what it can and cannot do

DC permits telehealth prescribing for specialty medications including Evenity. A licensed DC provider can conduct the initial evaluation by video, review DXA and lab results, and transmit the prescription electronically. The prescriber must hold an active DC license; an out-of-state telehealth provider cannot lawfully prescribe to a DC resident without one.

Telehealth does not replace the injection visit. The drug ships as prefilled syringes requiring correct subcutaneous technique, and most DC practices supervise at least the first few doses in person or through home health nursing before allowing self-injection, if self-injection is offered at all.

DC has a telehealth payment parity requirement for private insurers, and DC Medicaid managed care plans generally cover telehealth-initiated specialty prescriptions once prior authorization criteria are met. Confirm current parity rules and MCO-specific coverage directly with the DC Department of Insurance, Securities and Banking or your plan, since insurance regulation details change and are not reproduced here as legal citations.

Labs and imaging required before starting

Insurers and prescribers typically require documentation of the following before the first dose:

• Serum calcium, generally expected within normal range (roughly 8.5 to 10.5 mg/dL). Hypocalcemia must be corrected and rechecked first.
• 25-hydroxyvitamin D, with correction of deficiency (often with high-dose D3 repletion) before starting.
• DXA scan showing qualifying bone density, commonly a T-score at or below -2.5, though some plans require -3.0 or a documented fragility fracture.
• Basic metabolic panel, mainly to assess renal function; the FDA label does not require dose adjustment for renal impairment, but clinicians still monitor it given the typical patient age.
• Cardiovascular history and risk assessment, given the boxed warning, including confirmation of no MI or stroke in the past 12 months.

Labs are usually drawn several weeks ahead of the target start date to allow time for correcting deficiencies and completing prior authorization.

Prior authorization: what actually happens

Every commercial insurer and DC Medicaid requires prior authorization for Evenity because it is a high-cost specialty biologic. A typical PA package includes the DXA report, calcium and vitamin D results, cardiovascular screening documentation, evidence of prior treatment failure or intolerance (commonly a bisphosphonate or denosumab), and a letter of medical necessity.

Federal and state rules generally require insurers to respond to urgent PA requests faster than routine ones, but the exact number of days, and how "urgent" is defined, varies by insurer and by whether the plan is fully insured, self-funded, Medicaid managed care, or Medicare Part B. Do not rely on a single turnaround estimate; ask the specific plan for its current PA timeline in writing.

DC Medicaid covers Evenity for severe osteoporosis with prior authorization, requiring appropriate ICD-10 documentation (osteoporosis codes with or without pathological fracture) and DXA results. Confirm current DC Medicaid formulary status and any fee-for-service versus MCO routing directly with the Centers for Medicare & Medicaid Services guidance or DC's Medicaid program, since formulary placement can change.

Pharmacy access and 503A dispensing

Evenity requires cold-chain storage and ships through specialty pharmacy channels rather than standard retail pharmacy stock. Common specialty pharmacy networks operate in DC, coordinating PA status and direct shipment to the home or administering clinic.

A 503A pharmacy is licensed to dispense medications under a patient-specific prescription. For a branded biologic like Evenity, a 503A pharmacy would dispense the commercial product itself rather than a compounded version, since there is no FDA-approved compounded or biosimilar alternative to romosozumab. Any pharmacy claiming to compound a "custom" romosozumab product should be treated as a red flag and confirmed against FDA guidance before use.

Patients near the Maryland or Virginia border should confirm that their delivery address and prescriber licensure align with DC jurisdiction if a DC-licensed pharmacy is filling the prescription.

The treatment course and what follows it

The FDA-approved regimen is two 105 mg subcutaneous injections (210 mg total) once monthly for 12 consecutive doses, with no approved extension beyond 12 months. Injection sites rotate among the abdomen, thigh, and upper arm.

Common adverse effects reported in the label include injection-site reactions, joint pain, and headache; exact frequency figures should be checked against the current FDA label rather than assumed from secondary sources. A separate large randomized trial (FRAME) reported meaningful gains in lumbar spine bone density with romosozumab compared with placebo at 12 months; the precise percentage increase commonly cited for this trial should be verified against the original publication before being used for patient counseling.

After the 12-month course, guidance from bone health specialists generally supports transitioning to an antiresorptive agent (a bisphosphonate or denosumab) to preserve the bone density gained. Stopping without a follow-on agent is associated with rapid loss of the gained bone density. This transition plan is best discussed with the prescriber before starting romosozumab, not after finishing it.

Cardiovascular safety: what is established and what is not

Established: Evenity carries an FDA boxed warning for cardiovascular risk and is contraindicated in patients with an MI or stroke in the prior 12 months, per the FDA prescribing information and FDA's general process for evaluating benefit-risk in individual patients through drug safety communications.

Plausible but requiring verification: the ARCH trial reported a numerically higher rate of cardiovascular events with romosozumab than with alendronate, but the exact rate difference cited in various secondary sources is inconsistent and should be checked against the original trial publication or a current systematic review before being treated as a fixed number.

Not established from the material available here: a precise, generalizable absolute cardiovascular risk increase that applies across all patient subgroups. Individual risk depends on baseline cardiovascular history, which is exactly why baseline screening is required before the first dose.

Cost and financial assistance

List price, copay assistance terms, and Medicare Part B coinsurance amounts for Evenity change over time and are not reproduced here as fixed figures. What is stable: Evenity is a physician-administered specialty biologic, typically billed under Medicare Part B rather than Part D when given in a clinical setting; commercial manufacturer copay assistance programs (see Amgen's patient support information) generally exclude patients on Medicare or Medicaid; and DC Medicaid's cost-sharing policy for approved specialty drugs should be confirmed directly with the program at the time of treatment, since cost-sharing rules and formulary tiers are revised periodically.

Transferring a prescription into DC

A patient moving to DC with an active romosozumab prescription needs a DC-licensed prescriber to verify the original prescription, confirm which monthly dose the patient is on, and resubmit prior authorization under the new prescriber's information. A new insurer generally requires a new PA. Bringing the original PA approval letter, DXA reports, and lab results speeds this process, and pharmacies within the same specialty network can sometimes transfer records internally. Whether an existing DXA scan is considered current enough to avoid repeating it depends on the specific insurer's policy, not a fixed DC-wide rule; confirm this with the receiving plan.

Evidence boundary

Established from FDA labeling: the approved indication, the 12-month/210 mg monthly regimen, the boxed cardiovascular warning, and the contraindication in patients with recent MI or stroke.

Established as general DC health policy: full-practice-authority nurse practitioner prescribing, telehealth permissibility for specialty prescriptions, and DC Medicaid's general willingness to cover Evenity with prior authorization.

Plausible but not verifiable from the sources available here: precise fracture-risk-reduction percentages, precise cardiovascular event rates, precise bone density gain percentages, and specific dollar costs. These come from trial reports and manufacturer materials that this draft could not independently confirm through a verified citation, and they should be checked against the primary trial publications or the current FDA label before being used in patient-facing materials.

Not established: any claim that a specific DC pharmacy, insurer, or timeline will produce a certain outcome. Prior authorization decisions, appeal windows, and formulary placement are plan-specific and change over time.

Verification checklist: stable facts vs. facts that expire

Verify current information with your insurer or DC Medicaid before making any actual coverage or treatment decisions based on this article.

Stable federal and clinical facts (safe to treat as durable, still confirm against the current label)

• Romosozumab-aqqg (Evenity) is FDA-approved for postmenopausal women with osteoporosis at high fracture risk.
• The approved regimen is two 105 mg subcutaneous injections monthly for 12 doses total, with no approved extension.
• The FDA label carries a boxed warning for cardiovascular risk and contraindicates use within 12 months of an MI or stroke.
• No FDA-approved biosimilar or compounded alternative to romosozumab exists; 503A pharmacies dispense the commercial product only.
• A follow-on antiresorptive agent is generally recommended after the 12-month course to preserve bone density gains.

Date-sensitive facts you must verify before acting (insurer, state, pharmacy, or price-dependent)

• Which specific insurers require step therapy (bisphosphonate or denosumab failure) before approving romosozumab, and what documentation each PA form requires.
• Current DC Medicaid formulary status, cost-sharing rules, and whether the request routes through fee-for-service or a specific MCO.
• Current PA turnaround times for your specific plan, not a general "5 to 7 day" estimate.
• Current list price, manufacturer copay assistance terms and eligibility, and Medicare Part B coinsurance amount.
• Whether a specific specialty pharmacy is in-network for your plan and can ship to your DC address.
• Whether your specific DC-licensed telehealth provider's license is active and unrestricted at the time of your visit.
• Whether a transferred-in DXA scan will be accepted as current by your new insurer, and for how long.

If any of these seven items has not been confirmed with a named, dated source in the last few weeks, treat the corresponding part of this article as background, not as a coverage guarantee.